Radioembolization for hepatocellular carcinoma: updated strategies and evolving clinical applications

Abstract

Primary liver cancer, particularly hepatocellular carcinoma (HCC), ranks among the top causes of cancer deaths worldwide. Traditionally, liver cancer has been associated with a dismal prognosis, which has led to extensive research into potential treatments. Over the past decade, there have been substantial advancements, particularly in the area of locoregional therapies such as radioembolization. This paper provides a summary of the expanding role of radioembolization in HCC treatment, emphasizing recent updates in therapeutic guidelines and ongoing clinical research.

Keywords

Hepatocellular carcinoma / radioembolization / yttrium-90 / dosimetry / immunotherapy

References

[1] Vogel A,Sapisochin G,Saborowski A.Hepatocellular carcinoma.Lancet2022;400:1345-62

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Salem R,Mouli S.Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology2016;151:1155-63.e2 PMCID:PMC5124387

[4] Kolligs FT,Jakobs T.Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.Liver Int2015;35:1715-21

[5] Chow PKH, Gandhi M, Tan SB, et al; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1913-21.

[6] Vilgrain V, Pereira H, Assenat E, et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624-36.

[7] Ricke J,Amthauer H.Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019;71:1164-74

[8] Lobo L,Picado O.Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis.Cardiovasc Intervent Radiol2016;39:1580-8

[9] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[10] Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v59-64.

[11] Kim HC.Radioembolization for the treatment of hepatocellular carcinoma.Clin Mol Hepatol2017;23:109-14 PMCID:PMC5497664

[12] Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22. PMCID:PMC3417764

[13] Sposito C.The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.Hepatobiliary Surg Nutr2018;7:487-9 PMCID:PMC6295389

[14] Reinders M,Lam M.Toxicity and dosimetry in SORAMIC study.J Hepatol2020;73:734-5

[15] Hermann AL, Dieudonné A, Ronot M, et al; SARAH Trial Group. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology 2020;296:673-84.

[16] Palmer DH,Vilgrain V,Chatellier G.Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.Future Oncol2020;16:4315-25

[17] Makary MS,Miller ED,Rikabi A.Long-term clinical outcomes of yttrium-90 transarterial radioembolization for hepatocellular carcinoma: a 5-year institutional experience.Acad Radiol2024;31:1828-35

[18] Aliseda D,Zozaya G.Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience.Cancers2023;15:733 PMCID:PMC9913597

[19] Gabr A,Johnson GE.Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.Eur J Nucl Med Mol Imaging2021;48:580-3

[20] Garin E,Laffont S.Clinical impact of ^99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with ⁹⁰Y-loaded microspheres.Eur J Nucl Med Mol Imaging2016;43:559-75 PMCID:PMC4731431

[21] Garin E,Edeline J.Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.J Nucl Med2015;56:339-46

[22] Garin E, Tselikas L, Guiu B, et al; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29.

[23] Lam M,Maccauro M.A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with yttrium-90: the TARGET study.Eur J Nucl Med Mol Imaging2022;49:3340-52 PMCID:PMC9308596

[24] Levillain H,Deroose CM.International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.Eur J Nucl Med Mol Imaging2021;48:1570-84 PMCID:PMC8113219

[25] Salem R,Lam M.Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.Eur J Nucl Med Mol Imaging2023;50:328-43 PMCID:PMC9816298

[26] van Doorn DJ,Burgmans MC.Liver decompensation as late complication in HCC patients with long-term response following selective internal radiation therapy.Cancers2021;13:5427 PMCID:PMC8582376

[27] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[28] Vitale A,Farinati F.Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy.Hepatology2020;72:2206-18

[29] Salem R,Kim E.Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study.Hepatology2021;74:2342-52 PMCID:PMC8596669

[30] Takayama T,Izumi N.Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial).Liver Cancer2022;11:209-18 PMCID:PMC9218617

[31] Uhlig J,Stein SM.Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.Eur Radiol2019;29:2679-89

[32] Kim E,Abboud G.Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study.Lancet Gastroenterol Hepatol2022;7:843-50

[33] Lewandowski RJ,Abouchaleh N.Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology2018;287:1050-8

[34] De la Garza-Ramos C,Croome KP.Radiation segmentectomy for the treatment of solitary hepatocellular carcinoma: outcomes compared with those of surgical resection.J Vasc Interv Radiol2022;33:775-85.e2

[35] Arndt L,Wagstaff W.Evaluation of medium-term efficacy of Y90 radiation segmentectomy vs percutaneous microwave ablation in patients with solitary surgically unresectable < 4 cm hepatocellular carcinoma: a propensity score matched study.Cardiovasc Intervent Radiol2021;44:401-13

[36] Mosenthal M,Cotler S.Locoregional therapies for hepatocellular carcinoma prior to liver transplant: comparative pathologic necrosis, radiologic response, and recurrence.J Vasc Interv Radiol2024;35:506-14

[37] Dhondt E,Hermie L.⁹⁰Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial.Radiology2022;303:699-710

[38] Chung SW,Shin H.Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients.Front Oncol2023;13:1081479 PMCID:PMC10013818

[39] Brown AM,Massani M.TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis.Cancer Med2023;12:2590-9 PMCID:PMC9939158

[40] Chow R,Jairam MP,Boldt G.Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data.Acta Oncol2022;61:484-94

[41] Young S,Ragulojan R.Local recurrence following a complete radiologic response in hepatocellular carcinoma patients: comparison of transarterial chemoembolisation and transarterial radioembolisation.Clin Radiol2024;79:371-7

[42] Wagenpfeil J,Bruners P.Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization.Front Radiol2024;4:1346550 PMCID:PMC10912470

[43] Hund HC,Matsuoka L.Effect of previous transarterial chemoembolization on survival and toxicity after yttrium-90 transarterial radioembolization of hepatocellular carcinoma in the radiation-emitting SIR-spheres in nonresectable liver tumor registry.J Vasc Interv Radiol2023;34:2147-54.e2

[44] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73 PMCID:PMC9630017

[45] Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

[46] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid2022;1:EVIDoa2100070

[47] Liu B,Meyers BM.Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis.Ann Palliat Med2023;12:1165-74

[48] Gabr A,Mouli S.Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy.Semin Intervent Radiol2019;36:343-8 PMCID:PMC6823042

[49] Vouche M,Atassi R.Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.J Hepatol2013;59:1029-36 PMCID:PMC5085290

[50] Garlipp B,Kupitz D.The impact of unilateral ⁹⁰Y-radioembolization on functional changes in the contralateral hepatic lobe: the prospective, open-label radioembolization, volumetry, and liver function measurements (REVoluTion) study.Ann Surg Open2021;2:e095 PMCID:PMC10455191

[51] Birgin E,Seyfried S.Contralateral liver hypertrophy and oncological outcome following radioembolization with ⁹⁰Y-microspheres: a systematic review.Cancers2020;12:294 PMCID:PMC7072354

[52] Garlipp B,Damm R.Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization.Hepatology2014;59:1864-73

[53] Tabone M,Russolillo N.Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience.J Gastrointest Oncol2020;11:84-90 PMCID:PMC7052761

[54] Serenari M,Cucchetti A.Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: a pilot study.Liver Transpl2021;27:1758-66 PMCID:PMC9290139

[55] Bargellini I,Boni G.Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion: validation of the milan prognostic score.J Vasc Interv Radiol2020;31:2028-32

[56] Jia Z,Tian F,Qin X.A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.Saudi J Gastroenterol2016;22:353-9 PMCID:PMC5051218

[57] Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

[58] Ricke J,Seidensticker M.Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.J Hepatol2021;75:1387-96

[59] Mejait A,Soret M.Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: a promising approach for improved survival.Clin Res Hepatol Gastroenterol2024;48:102282

[60] Tai D,Gogna A.Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.Lancet Gastroenterol Hepatol2021;6:1025-35

[61] de la Torre-Aláez M,Varela M.Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.J Immunother Cancer2022;10:e005457 PMCID:PMC9716796

[62] Lee YB,Cho EJ.A phase I/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma.Clin Cancer Res2023;29:3650-8

[63] Torkian P,Farsad K,Golzarian J.Cancer immunology: impact of radioembolization of hepatocellular carcinoma on immune response modulation.AJR Am J Roentgenol2023;220:863-72

[64] Yu Q,Ungchusri E.Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: a preliminary report of safety and feasibility.J Interv Med2023;6:187-93 PMCID:PMC10831372

[65] Villalobos A,Little O.Safety and efficacy of concurrent atezolizumab/bevacizumab or nivolumab combination therapy with yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma.Curr Oncol2023;30:10100-10 PMCID:PMC10742675

[66] Zhan C,Shanbhogue KP.Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma.J Vasc Interv Radiol2020;31:25-34

[67] Yu S,Keane B.A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma.Oncologist2024;29:270-e413 PMCID:PMC10911903

[68] Kennedy AS,Fakih M.Multidisciplinary delphi consensus on safety of combining transarterial radioembolization with yttrium-90 microspheres with systemic anticancer agents for the treatment of liver malignancy.J Vasc Interv Radiol2024;35:1253-67.e1